NCT00482417

Brief Summary

Efficacy and Safety Study of MK0359 in Patients with Arthritis

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for phase_2 rheumatoid-arthritis

Timeline
Completed

Started Dec 2002

Shorter than P25 for phase_2 rheumatoid-arthritis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2002

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2003

Completed
4.1 years until next milestone

First Submitted

Initial submission to the registry

June 1, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 5, 2007

Completed
Last Updated

November 20, 2015

Status Verified

November 1, 2015

Enrollment Period

5 months

First QC Date

June 1, 2007

Last Update Submit

November 19, 2015

Conditions

Rheumatoid Arthritis

Interventions

MK0359DRUG

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You are 18-65 years of age and have Rheumatoid Arthritis
  • You must be able to read and understand patient questionnaires

You may not qualify if:

  • You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 1, 2007

First Posted

June 5, 2007

Study Start

December 1, 2002

Primary Completion

May 1, 2003

Study Completion

May 1, 2003

Last Updated

November 20, 2015

Record last verified: 2015-11